Core Viewpoint - The stock of the company,药捷安康-B (02617), has seen a significant increase, reaching a new high of 64.8 HKD, nearly quadrupling from its IPO price of 13.15 HKD, indicating strong market performance and investor interest [1] Group 1: Stock Performance - The stock price increased by over 8% during trading, peaking at 64.8 HKD, and is currently up 5.26% at 63 HKD with a trading volume of 11.809 million HKD [1] - The stock has appreciated nearly four times since its initial public offering [1] Group 2: Clinical Research - The company announced the completion of the first patient dosing in a Phase II clinical study for its core product,替恩戈替尼, in combination with 康方生物's 开坦尼 and 依达方 for the treatment of advanced hepatocellular carcinoma [1] - The study aims to evaluate the safety and efficacy of the combination therapy, targeting patients who have not previously received systemic anti-tumor therapy or have failed standard treatment for advanced hepatocellular carcinoma [1] Group 3: Index Inclusion - On August 22, the Hang Seng Index Company announced that the company will be included in the Hang Seng Composite Index, with changes effective after market close on September 5 and active from September 8 [1] - According to Huatai Securities, the company may be included in the Hong Kong Stock Connect due to meeting various criteria including market capitalization, liquidity, and listing duration [1]

Group 1 - The core product of the company, Tiengogatinib, has completed the first patient dosing in a Phase II clinical study for the treatment of advanced hepatocellular carcinoma in combination with Kangfang Biotech's Ketanib and Idafos. The study aims to evaluate the safety and efficacy of the combination therapy for patients who have not received systemic anti-tumor therapy or have failed standard treatment for advanced liver cancer [1] - The stock price of the company surged over 8%, reaching a new high of 64.8 HKD, which is nearly four times the IPO price of 13.15 HKD. As of the latest update, the stock is trading at 63 HKD with a transaction volume of 11.809 million HKD [1] - The company has been included in the Hang Seng Composite Index, with the changes set to take effect after the market closes on September 5 and will be effective from September 8. This inclusion may lead to adjustments in the eligible stocks for the Hong Kong Stock Connect, as the company meets various criteria including market capitalization, liquidity, and listing duration [1]

Core Viewpoint - The company has completed the first patient dosing in a Phase II clinical trial evaluating the combination of Tinengotinib with Kanfang Biotech's anti-cancer drugs for advanced hepatocellular carcinoma [1][2] Group 1: Clinical Trial Details - The trial is an open-label, multicenter Phase II study conducted in China, aimed at assessing the efficacy and safety of Tinengotinib in combination with Kanfang's drugs, Kadyuoni (PD-1/CTLA-4) and Yidafang (PD-1/VEGF) [2] - The primary objective of the trial is to evaluate the safety and effectiveness of the combination therapies compared to Tinengotinib monotherapy in patients with advanced hepatocellular carcinoma who have not received prior systemic anti-tumor treatment or have failed standard treatment [2] Group 2: Collaboration and Development - The company has established a collaboration agreement with Kanfang Biotech to jointly develop clinical combination therapies in the field of hepatocellular carcinoma [2]

Core Viewpoint - The company announced the initiation of a Phase II clinical trial for its core product, Tinengotinib (TT-00420), in combination with other therapies for the treatment of advanced hepatocellular carcinoma (HCC) [1] Group 1: Clinical Trial Details - The trial is an open-label, multicenter Phase II study conducted in China [1] - The primary objective is to evaluate the safety and efficacy of Tinengotinib in combination with Kanfar Biotech's Katanib (PD-1/CTLA-4) and Yida Pharma's Yivofisi (PD-1/VEGF) [1] - The target population includes patients with advanced HCC who have not previously received systemic anti-tumor therapy or have failed standard treatment [1] Group 2: Collaboration and Development - The company has entered into a collaboration agreement with Kanfar Biotech to jointly develop clinical combination therapies in the field of hepatocellular carcinoma [1]

值得注意的是，公司中期财报透露，依沃西单抗(AK112)于2024年5月获得国家药品监督管理局的批 准，用于EGFR-TKI治疗进展的局部晚期或转移性非鳞状非小细胞肺癌(nsq-NSCLC)，针对该适应症的 中国III期HARMONi-A研究(AK112-301)已达到总生存期(OS)临床终点，展现出具有统计学和临床意义 的OS获益，详细数据将在未来国际学术会议上发表。 智通财经APP获悉，康方生物(09926)高开近5%，截至发稿，涨4.73%，报177港元，成交额3.81亿港 元。 消息面上，康方生物发布中期业绩，上半年收入14.12亿元人民币，同比增加37.75%；毛利11.21亿元， 同比增加18.82%。公告称，商业销售收入约为14.02亿元，较去年同期的9.39亿元同比增加49.20%，主 要得益于开坦尼(卡度尼利，PD-1/CTLA-4)和依达方(依沃西，PD-1/VEGF)首次纳入国家医保目录适应 症后带来的销售增长，以及新获批的一线适应症带来的销售贡献。此外，公司新获批上市的2款产品伊 喜宁(伊努西，PCSK9)和爱达罗(依若奇，IL-12/IL-23)的商业化顺利启动并开始释放销售。 ...

值得注意的是，公司中期财报透露，依沃西单抗(AK112)于2024年5月获得国家药品监督管理局的批 准，用于EGFR-TKI治疗进展的局部晚期或转移性非鳞状非小细胞肺癌(nsq-NSCLC)，针对该适应症的 中国III期HARMONi-A研究(AK112-301)已达到总生存期(OS)临床终点，展现出具有统计学和临床意义 的OS获益，详细数据将在未来国际学术会议上发表。 康方生物(09926)高开近5%，截至发稿，涨4.73%，报177港元，成交额3.81亿港元。 消息面上，康方生物发布中期业绩，上半年收入14.12亿元人民币，同比增加37.75%；毛利11.21亿元， 同比增加18.82%。公告称，商业销售收入约为14.02亿元，较去年同期的9.39亿元同比增加49.20%，主 要得益于开坦尼(卡度尼利，PD-1/CTLA-4)和依达方(依沃西，PD-1/VEGF)首次纳入国家医保目录适应 症后带来的销售增长，以及新获批的一线适应症带来的销售贡献。此外，公司新获批上市的2款产品伊 喜宁(伊努西，PCSK9)和爱达罗(依若奇，IL-12/IL-23)的商业化顺利启动并开始释放销售。 ...